SynthesisOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Prevalence and relative risk of fractures and osteoporosis in patients with ankylosing spondylitis: a systematic review and meta-analysis.
Synthesis in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Underestimation of fracture risk by conventional FRAX thresholds in axial spondyloarthritis: a proposal for disease-specific thresholds.Therapeutic advances in musculoskeletal disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with ankylosing spondylitis are at greater risk of fractures and osteoporosis. This meta-analysis reveals their fracture and osteoporosis prevalence exceeds 13%. Two clinical indices, BASDAI and mSASSS, significantly correlate with fracture risk. These findings support early screening and targeted management to prevent skeletal complications and improve patient outcomes. Patients with Ankylosing Spondylitis (AS) face an elevated risk of fractures and osteoporosis, which negatively impact quality of life and increase healthcare costs. This study systematically evaluates the prevalence of these conditions in AS patients and analyzes the associated risk factors. As of October 10, 2024, we conducted a systematic search of PubMed, Embase, the Cochrane Library, and Web of Science for epidemiological studies on the risk factors or prevalence of fractures and osteoporosis in AS. Effect sizes were pooled using fixed- or random-effects models, with subgroup and sensitivity analyses. Publication bias was evaluated using funnel plots and Begg's or Egger's test. A total of 28 studies were included in the final analysis. The overall fracture prevalence in AS patients was 13% (95% CI: 9%-17%), vertebral fracture prevalence was 14% (95% CI: 9%-19%), and osteoporosis prevalence was 14% (95% CI: 10%-19%). AS was significantly associated with vertebral fractures (OR = 2.26; 95% CI: 1.70-3.00) and non-vertebral fractures (OR = 1.24; 95% CI: 1.02-1.50). Among AS assessment indices, BASDAI (OR = 1.05; 95% CI: 1.02-1.08) and mSASSS (OR = 1.04; 95% CI: 1.01-1.06) were significantly associated with fracture risk, while BASFI and BASRI were not. AS significantly increases the risk of fractures and osteoporosis in patients. The BASDAI and mSASSS scoring systems can help predict fracture risk, enabling enhanced early identification and monitoring of complications in AS patients. This approach may ultimately improve long-term health outcomes and quality of life for affected individuals.
Indexed as
Identifiers
41575558What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.